Healthcare Expenditures for the Treatment of Patients Infected with Hepatitis C Virus in Japan
- 24 Downloads
The recently developed direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infections are costly. Cost-effectiveness analyses of DAAs require accurate healthcare expenditure estimates for the various HCV disease states, but few studies have produced such estimates using national-level data. This study utilized nationally representative data to estimate the healthcare expenditure for each HCV disease state.
We identified all patients infected with HCV between April 2010 and March 2018 from a nationwide administrative claims database in Japan. Monthly patient-level healthcare expenditures were calculated for the following disease states: chronic hepatitis C (CHC), compensated cirrhosis (CC), decompensated cirrhosis (DC), and hepatocellular carcinoma (HCC). The expenditures for the CHC and CC states were also compared before DAA treatment and after sustained virologic response (SVR) was achieved. A longitudinal two-part model was employed to estimate the healthcare expenditures for each state.
During the study period, 1,564,043 patients with 146,488,137 patient-months of data met the inclusion criteria. The year of valuation was 2017. The mean monthly healthcare expenditures per patient (95% confidence intervals) for the pre-DAA CHC, CC, DC, and HCC states were US$267 (US$267–268), US$428 (US$427–429), US$666 (US$663–669), and US$969 (US$966–972), respectively. The mean monthly healthcare expenditures per patient for the post-SVR (≥ 2 years) CHC and CC states were US$176 (US$176–177) and US$238 (US$236–240), respectively. Healthcare expenditure increased with increasing age in all disease states (P < 0.05).
These healthcare expenditure estimates from a nationally representative sample have potential applications in cost-effectiveness analyses of DAAs.
We are grateful to Mr. S. Kondo and Mr. S. Yamakawa from Denno Labo Corporation for their support in extracting the study sample from the NDB.
HF, YY, DS, SO, SN, RW, and OT contributed to the study’s conception and design; HF carried out the analysis of the data and drafted the manuscript. All authors were involved in the interpretation of the results, as well as in the editing and revision of the manuscript.
Compliance with Ethical Standards
Conflict of interest
Haruhisa Fukuda, Yoshihiko Yano, Daisuke Sato, Sachiko Ohde, Shinichi Noto, Ryo Watanabe, and Osamu Takahashi have no conflicts of interest, financial or otherwise, to declare.
This work was supported by a Grant-in-Aid for Health Sciences Research from the Ministry of Health, Labour and Welfare of Japan (Grant number: H30-Seisaku-Shitei-003) and JSPS KAKENHI Grant number 17H04144.
- 1.Ministry of Health, Labour and Welfare. Estimates of national medical care expenditure 2015. http://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/15/dl/kekka.pdf. Accessed 19 Sept 2019.
- 2.Ministry of Health, Labour and Welfare. Trends in medical care expenditure FY2016. http://www.mhlw.go.jp/topics/medias/year/16/dl/iryouhi_data.pdf. Accessed 19 Sept 2019.
- 3.Ministry of Health, Labour and Welfare. NDB Open Data Japan 2014. http://www.mhlw.go.jp/seisakunitsuite/bunya/0000139390.html. Accessed 19 Sept 2019.
- 4.Ministry of Health, Labour and Welfare. NDB Open Data Japan 2015. http://www.mhlw.go.jp/seisakunitsuite/bunya/0000177221.html. Accessed 19 Sept 2019.
- 7.Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15(6):645–53.CrossRefGoogle Scholar
- 19.McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm. 2011;17(7):531–46.PubMedGoogle Scholar
- 20.Ikeda S, Kobayashi M. Research on health-economics of various initiatives related to viral liver diseases, Ministry of Health, Labour and Welfare, Japan (PI: Hirao T) 2014;119–121. Accessed 10 Feb 2018. (in Japanese).Google Scholar
- 21.Ikeda S. Research on health-economics of various initiatives related to viral liver diseases, Ministry of Health, Labour and Welfare, Japan (PI: Hirao T) 2015;24–28. Accessed 10 Feb 2018. (in Japanese).Google Scholar
- 22.Ikeda S. Research on health-economics of various initiatives related to viral liver diseases, Ministry of Health, Labour and Welfare, Japan (PI: Hirao T) 2016;22–31. Accessed 10 Feb 2018. (in Japanese).Google Scholar
- 27.Committee for Guideline Development for Hepatitis Treatment, The Japan Society of Hepatology. Treatment guidelines for hepatitis C (sixth edition). https://www.jsh.or.jp/files/uploads/HCV_GL_ver6_Dec28_v2.pdf. Accessed 10 Feb 2018.